Sep 29, 2026 4:01 pm EDT Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Sep 23, 2026 7:00 am EDT Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
Sep 4, 2026 4:05 pm EDT Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Aug 6, 2026 7:00 am EDT Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
Jun 16, 2026 7:00 am EDT Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
